[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f27c12d42fdcd7d18ca65a8c1ddf3f68baa4f282f4e98209e316c6f95a687efc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756141620,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "id": 136554219,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f27c12d42fdcd7d18ca65a8c1ddf3f68baa4f282f4e98209e316c6f95a687efc"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress",
    "summary": "– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement in overall seizure burden and seizure free days observed with ongoing treatment – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company d",
    "url": "https://finnhub.io/api/news?id=81db572aae98abda9363ac6d61315a28ef55390217c2a115a4c4a259a0b8824c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756119600,
      "headline": "Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress",
      "id": 136508452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement in overall seizure burden and seizure free days observed with ongoing treatment – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company d",
      "url": "https://finnhub.io/api/news?id=81db572aae98abda9363ac6d61315a28ef55390217c2a115a4c4a259a0b8824c"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress",
    "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., August 25, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC), taking place August 30 – September 3, 2025 in Lisbon, Portugal. Zorevunersen, an investigational antisense oligonucleotide,",
    "url": "https://finnhub.io/api/news?id=a72e52561a2dc76d1f2eb132bb71482ad08afdf273dec72b2af61c8dbc49d69a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756119600,
      "headline": "Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress",
      "id": 136508451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., August 25, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC), taking place August 30 – September 3, 2025 in Lisbon, Portugal. Zorevunersen, an investigational antisense oligonucleotide,",
      "url": "https://finnhub.io/api/news?id=a72e52561a2dc76d1f2eb132bb71482ad08afdf273dec72b2af61c8dbc49d69a"
    }
  },
  {
    "ts": null,
    "headline": "Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)",
    "summary": "TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. LEQEMBI received the European Commission (EC) approval in April 2025",
    "url": "https://finnhub.io/api/news?id=f589be1dc667f9be6687c7760da76c672078c070207881a906361c507bc6e319",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756105200,
      "headline": "Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)",
      "id": 136508453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. LEQEMBI received the European Commission (EC) approval in April 2025",
      "url": "https://finnhub.io/api/news?id=f589be1dc667f9be6687c7760da76c672078c070207881a906361c507bc6e319"
    }
  }
]